Epidemiology of Schizophrenia in Bulgaria

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00984373
First received: September 24, 2009
Last updated: February 2, 2010
Last verified: February 2010
  Purpose

The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of:

  • Patient characteristics.
  • Diagnostic and treatment approaches: initial and subsequent.

Condition
Schizophrenia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 440
Study Start Date: September 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary Care Clinic

Criteria

Inclusion Criteria:

  • Patients with schizophrenia
  • Above 18 years
  • Signed Informed consent

Exclusion Criteria:

  • Below 18 years
  • Consent refused
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00984373

Locations
Bulgaria
Research Site
Burgas, Bulgaria
Research Site
Pazardzhik, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vidin, Bulgaria
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00984373     History of Changes
Other Study ID Numbers: NIS-NBG-SER-2009/1
Study First Received: September 24, 2009
Last Updated: February 2, 2010
Health Authority: Bulgaria: Ministry of Health

Keywords provided by AstraZeneca:
Schizophrenia epidemiology
Schizophrenic patients' social and health characteristics

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on August 25, 2014